Managing Diabetes During Chemotherapy

Introduction to Chemotherapy-Related Challenges

• Chemotherapy poses several challenges for patients on diabetes medications, including decreased oral intake, potential dehydration, altered metabolism, and possible drug interactions between chemotherapeutic agents and antidiabetic medications, significantly increasing hypoglycemia risk, especially with sulfonylureas like glimepiride 1
• Glimepiride should be used with extreme caution during chemotherapy due to increased risk of hypoglycemia, and temporary discontinuation or dose reduction should be considered, especially on treatment days with highly emetogenic regimens 2

Dose Adjustment and Monitoring

• Monitor renal function closely as chemotherapy may affect kidney function, and glimepiride should be used with caution in patients with renal impairment 2
• The American Journal of Transplantation recommends glimepiride be used with caution in patients with renal impairment, and if eGFR drops below 50 mL/min/1.73m², consider switching to glipizide which is safer in renal impairment 2
• Semaglutide has no dose adjustment requirements based on renal function and can be safely continued during chemotherapy, providing steady glycemic control with weekly dosing and a lower risk of hypoglycemia compared to sulfonylureas, as recommended by the Endocrine Society 1
• Monitor renal function when initiating or escalating doses of semaglutide, and start with lower doses (e.g., 1 mg daily of glimepiride) if continuing during treatment, as suggested by the Endocrine Society 1

Glycemic Control and Medication Management

• Implement frequent capillary blood glucose monitoring (4-6 times daily) during chemotherapy cycles, and consider continuous glucose monitoring when available to detect hypoglycemic episodes, as recommended by the National Comprehensive Cancer Network and the Endocrine Society 1, 3, 4
• Reassess glycemic control after each chemotherapy cycle, and consider temporary insulin therapy if glycemic control becomes erratic, especially for patients on sulfonylureas like glimepiride, who face increased risk of hypoglycemia due to decreased oral intake, potential dehydration, and possible drug interactions 1, 3, 4
• Consider temporary insulin therapy if glycemic control becomes erratic during chemotherapy, as it provides more flexible dosing based on intake and glucose levels 2
• Switch to a medication with lower hypoglycemia risk if appropriate for the patient's overall condition, and reassess medication regimen after completion of chemotherapy 2
• For patients on highly emetogenic regimens, such as those with cisplatin, consider holding glimepiride on treatment days, monitoring for both hyperglycemia and hypoglycemia, and considering temporary insulin therapy if needed, as recommended by the National Comprehensive Cancer Network 3

Sulfonylurea Therapy in Renal Impairment

• Glipizide is the preferred sulfonylurea for patients with kidney disease, as it does not have active metabolites and is not dependent on kidney elimination, making it a safer option, as stated by the American Journal of Kidney Diseases and Diabetes Care 5, 6, 7
• Glyburide should be avoided in patients with renal impairment due to its active metabolites that accumulate and increase the risk of hypoglycemia, as reported by the American Journal of Kidney Diseases and Diabetes Care 5, 6, 7
• The following table summarizes the recommended sulfonylurea therapy based on eGFR:

• Patients with kidney disease have two major risk factors for hypoglycemia when taking sulfonylureas: decreased drug clearance and impaired renal gluconeogenesis, as reported by the American Journal of Kidney Diseases 6

Antiemetic Protocols and Chemotherapy-Induced Diarrhea

• Follow antiemetic protocols with 5-HT3 antagonists, dexamethasone, and NK-1 receptor antagonists, as recommended by the National Comprehensive Cancer Network, and be aware that dexamethasone may cause hyperglycemia, requiring additional monitoring 3
• Monitor for chemotherapy-induced diarrhea, which may affect absorption of oral medications, and use loperamide for grade 1-2 diarrhea or consider octreotide for grade 3-4 diarrhea, as recommended by the American Society of Clinical Oncology, and maintain hydration to prevent acute kidney injury 8